ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday

ProKidney (NASDAQ:PROK) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect ProKidney to post earnings of ($0.16) per share for the quarter.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The business had revenue of $0.08 million for the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProKidney Price Performance

ProKidney stock opened at $0.64 on Thursday. The stock’s fifty day moving average is $0.86 and its two-hundred day moving average is $1.42. The stock has a market cap of $187.41 million, a PE ratio of -1.16 and a beta of 1.50. ProKidney has a 1-year low of $0.46 and a 1-year high of $4.44.

Insider Buying and Selling

In other ProKidney news, insider Control Empresarial De Capital acquired 268,105 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $0.73 per share, with a total value of $195,716.65. Following the purchase, the insider now owns 72,862,330 shares in the company, valued at approximately $53,189,500.90. The trade was a 0.37 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders purchased a total of 1,787,716 shares of company stock valued at $1,175,419 over the last three months. 41.49% of the stock is currently owned by company insiders.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.